Upadacitinib (Rinvoq®) accepted for restricted use within NHS Scotland for treatment of moderate to severe active rheumatoid arthritis

Treatment is restricted to patients with severe disease (DAS28> 5.1) that has not responded to intensive therapy with a combination of conventional DMARDs and in severe disease inadequately controlled by a TNF antagonist in whom rituximab is not appropriate.

Source:

Scottish Medicines Consortium